|
1. Berger, S.L., et al., An operational definition of epigenetics. Genes Dev, 2009. 23(7): p. 781-3. 2. Crews, D. and J.A. McLachlan, Epigenetics, evolution, endocrine disruption, health, and disease. Endocrinology, 2006. 147(6 Suppl): p. S4-10. 3. Bird, A., Perceptions of epigenetics. Nature, 2007. 447(7143): p. 396-8. 4. Bannister, A.J. and T. Kouzarides, Regulation of chromatin by histone modifications. Cell Res, 2011. 21(3): p. 381-95. 5. Holoch, D. and D. Moazed, RNA-mediated epigenetic regulation of gene expression. Nat Rev Genet, 2015. 16(2): p. 71-84. 6. Fraga, M.F., et al., Epigenetic differences arise during the lifetime of monozygotic twins. Proc Natl Acad Sci U S A, 2005. 102(30): p. 10604-9. 7. Kaminsky, Z.A., et al., DNA methylation profiles in monozygotic and dizygotic twins. Nat Genet, 2009. 41(2): p. 240-5. 8. Kornberg, R.D., Chromatin structure: a repeating unit of histones and DNA. Science, 1974. 184(4139): p. 868-71. 9. Zhang, Y. and D. Reinberg, Transcription regulation by histone methylation: interplay between different covalent modifications of the core histone tails. Genes Dev, 2001. 15(18): p. 2343-60. 10. Barski, A., et al., High-resolution profiling of histone methylations in the human genome. Cell, 2007. 129(4): p. 823-37. 11. Heintzman, N.D., et al., Histone modifications at human enhancers reflect global cell-type-specific gene expression. Nature, 2009. 459(7243): p. 108-12. 12. Mosammaparast, N. and Y. Shi, Reversal of histone methylation: biochemical and molecular mechanisms of histone demethylases. Annu Rev Biochem, 2010. 79: p. 155-79. 13. Shi, Y., et al., Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. Cell, 2004. 119(7): p. 941-53. 14. Shi, Y.J., et al., Regulation of LSD1 histone demethylase activity by its associated factors. Mol Cell, 2005. 19(6): p. 857-64. 15. Wissmann, M., et al., Cooperative demethylation by JMJD2C and LSD1 promotes androgen receptor-dependent gene expression. Nat Cell Biol, 2007. 9(3): p. 347-53. 16. Tsukada, Y., et al., Histone demethylation by a family of JmjC domain-containing proteins. Nature, 2006. 439(7078): p. 811-6. 17. Klose, R.J., E.M. Kallin, and Y. Zhang, JmjC-domain-containing proteins andhistone demethylation. Nat Rev Genet, 2006. 7(9): p. 715-27. 18. Berry, W.L. and R. Janknecht, KDM4/JMJD2 histone demethylases: epigenetic regulators in cancer cells. Cancer Res, 2013. 73(10): p. 2936-42. 19. Gray, S.G., et al., Functional characterization of JMJD2A, a histone deacetylase- and retinoblastoma-binding protein. J Biol Chem, 2005. 280(31): p. 28507-18. 20. Zhang, D., H.G. Yoon, and J. Wong, JMJD2A is a novel N-CoR-interacting protein and is involved in repression of the human transcription factor achaete scute-like homologue 2 (ASCL2/Hash2). Mol Cell Biol, 2005. 25(15): p. 6404-14. 21. Berry, W.L., et al., Oncogenic features of the JMJD2A histone demethylase in breast cancer. Int J Oncol, 2012. 41(5): p. 1701-6. 22. Li, B.X., et al., Effects of siRNA-mediated knockdown of jumonji domain containing 2A on proliferation, migration and invasion of the human breast cancer cell line MCF-7. Exp Ther Med, 2012. 4(4): p. 755-761. 23. Li, B.X., et al., Effects of RNA interference-mediated gene silencing of JMJD2A on human breast cancer cell line MDA-MB-231 in vitro. J Exp Clin Cancer Res, 2011. 30: p. 90. 24. Kim, T.D., et al., The JMJD2A demethylase regulates apoptosis and proliferation in colon cancer cells. J Cell Biochem, 2012. 113(4): p. 1368-76. 25. Black, J.C., et al., Conserved antagonism between JMJD2A/KDM4A and HP1gamma during cell cycle progression. Mol Cell, 2010. 40(5): p. 736-48. 26. Fu, L., et al., HIF-1alpha-induced histone demethylase JMJD2B contributes to the malignant phenotype of colorectal cancer cells via an epigenetic mechanism. Carcinogenesis, 2012. 33(9): p. 1664-73. 27. Li, W., et al., Histone demethylase JMJD2B is required for tumor cell proliferation and survival and is overexpressed in gastric cancer. Biochem Biophys Res Commun, 2011. 416(3-4): p. 372-8. 28. Toyokawa, G., et al., The histone demethylase JMJD2B plays an essential role in human carcinogenesis through positive regulation of cyclin-dependent kinase 6. Cancer Prev Res (Phila), 2011. 4(12): p. 2051-61. 29. Beyer, S., et al., The histone demethylases JMJD1A and JMJD2B are transcriptional targets of hypoxia-inducible factor HIF. J Biol Chem, 2008. 283(52): p. 36542-52. 30. Pollard, P.J., et al., Regulation of Jumonji-domain-containing histone demethylases by hypoxia-inducible factor (HIF)-1alpha. Biochem J, 2008. 416(3): p. 387-94. 31. Luo, W., et al., Histone demethylase JMJD2C is a coactivator for hypoxia-inducible factor 1 that is required for breast cancer progression. Proc Natl Acad Sci U S A, 2012. 109(49): p. E3367-76. 32. Liu, G., et al., Genomic amplification and oncogenic properties of the GASC1 histone demethylase gene in breast cancer. Oncogene, 2009. 28(50): p. 4491-500. 33. Loh, Y.H., et al., Jmjd1a and Jmjd2c histone H3 Lys 9 demethylases regulate self-renewal in embryonic stem cells. Genes Dev, 2007. 21(20): p. 2545-57. 34. Chu, C.H., et al., KDM4B as a target for prostate cancer: structural analysis and selective inhibition by a novel inhibitor. J Med Chem, 2014. 57(14): p. 5975-85. 35. Cloos, P.A., et al., The putative oncogene GASC1 demethylates tri- and dimethylated lysine 9 on histone H3. Nature, 2006. 442(7100): p. 307-11. 36. Duan, L., et al., KDM4/JMJD2 Histone Demethylase Inhibitors Block Prostate Tumor Growth by Suppressing the Expression of AR and BMYB-Regulated Genes. Chem Biol, 2015. 22(9): p. 1185-96. 37. Coffey, K., et al., The lysine demethylase, KDM4B, is a key molecule in androgen receptor signalling and turnover. Nucleic Acids Res, 2013. 41(8): p. 4433-46. 38. Shin, S. and R. Janknecht, Activation of androgen receptor by histone demethylases JMJD2A and JMJD2D. Biochem Biophys Res Commun, 2007. 359(3): p. 742-6. 39. 台灣癌症登記中心 . 40. 國家衛生研究院 : 前列腺癌臨床診療指引 . 41. 荷爾蒙療法失敗之轉移性前列腺癌診指引及最新治方簡介 . 42. Murray, C.W. and D.C. Rees, The rise of fragment-based drug discovery. Nat Chem, 2009. 1(3): p. 187-92. 43. Bavetsias, V., et al., 8-Substituted Pyrido[3,4-d]pyrimidin-4(3H)-one Derivatives As Potent, Cell Permeable, KDM4 (JMJD2) and KDM5 (JARID1) Histone Lysine Demethylase Inhibitors. J Med Chem, 2016. 59(4): p. 1388-409. 44. Barve, A., et al., Metabolism, oral bioavailability and pharmacokinetics of chemopreventive kaempferol in rats. Biopharm Drug Dispos, 2009. 30(7): p. 356-65. 45. Keraliya, R.A., et al., Osmotic drug delivery system as a part of modified release dosage form. ISRN Pharm, 2012. 2012: p. 528079. 46. Seguin, J., et al., Liposomal encapsulation of the natural flavonoid fisetin improves bioavailability and antitumor efficacy. Int J Pharm, 2013. 444(1-2): p.146-54. 47. Wang, L.H., Molecular signaling regulating anchorage-independent growth of cancer cells. Mt Sinai J Med, 2004. 71(6): p. 361-7. |